^
Association details:
| Biomarker: | HLA-A*03 |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Published date:
01/01/2022
Excerpt:
Patients with HLA-A*03 had shorter progression-free survival in the pooled patient population from the three CheckMate clinical trials of nivolumab for renal cell carcinoma (HR 1·31, 1·01–1·71; p=0·044), but not in those receiving control (everolimus) therapies....HLA-A*03 was associated with shorter progression-free survival in patients receiving ICI in the JAVELIN Renal 101 randomised clinical trial for renal cell carcinoma (avelumab plus axitinib; HR 1·59 per HLA-A*03 allele, 1·16–2·16; p=0·0036), but not in those receiving control (sunitinib) therapy.
DOI:
10.1016/S1470-2045(21)00582-9
Source:
Title:
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Published date:
12/09/2021
Excerpt:
The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy....Patients with HLA-A*03 had shorter progression-free survival in the pooled patient population from the three CheckMate clinical trials of nivolumab for renal cell carcinoma (HR 1·31, 1·01-1·71; p=0·044), but not in those receiving control (everolimus) therapies.
DOI:
10.1016/S1470-2045(21)00582-9
